Bone loss often occurs as a side effect in men who receive hormone-deprivation therapy for their advanced prostate cancer.

However, according to a new study, bone-strengthening drugs Fosamax may help to avoid the damage.

Earlier it was found that the drug prevent bone loss in patients on hormone-deprivation therapy. And now the current follow-up shows that two years of the drug offers even greater protection to men.

Dr. Neil M. Resnick, who is a professor of medicine in the department of geriatrics in Pittsburg University, says that: “In aging population, the risk of age related diseases is greatly increasing and prostate cancer is one of the commonest among these risks.” Read the rest of this entry